Trials / Completed
CompletedNCT03362190
ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)
A Phase 2A Open-label Trial to Assess the Safety of ZIMURA™ (Anti-C5) Administered in Combination With LUCENTIS® 0.5 mg in Treatment Naive Subjects With Neovascular Age Related Macular Degeneration
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Ophthotech Corporation · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
To assess the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Lucentis® 0.5 mg in treatment naïve subjects with neovascular age related macular degeneration (NVAMD)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avacincaptad Pegol | Avacincaptad Pegol in combination with Lucentis |
| DRUG | Lucentis | Avacincaptad Pegol in combination with Lucentis |
Timeline
- Start date
- 2017-10-11
- Primary completion
- 2018-10-18
- Completion
- 2018-10-18
- First posted
- 2017-12-05
- Last updated
- 2025-06-10
- Results posted
- 2022-02-02
Locations
28 sites across 3 countries: United States, Hungary, Latvia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03362190. Inclusion in this directory is not an endorsement.